ZA984849B - Compositions. - Google Patents

Compositions.

Info

Publication number
ZA984849B
ZA984849B ZA9804849A ZA984849A ZA984849B ZA 984849 B ZA984849 B ZA 984849B ZA 9804849 A ZA9804849 A ZA 9804849A ZA 984849 A ZA984849 A ZA 984849A ZA 984849 B ZA984849 B ZA 984849B
Authority
ZA
South Africa
Prior art keywords
compositions
Prior art date
Application number
ZA9804849A
Other languages
English (en)
Inventor
Roger Petrus Gerebe Vandecruys
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA984849B publication Critical patent/ZA984849B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ZA9804849A 1997-06-05 1998-06-04 Compositions. ZA984849B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711643.8A GB9711643D0 (en) 1997-06-05 1997-06-05 Glass thermoplastic systems

Publications (1)

Publication Number Publication Date
ZA984849B true ZA984849B (en) 1999-12-06

Family

ID=10813624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9804849A ZA984849B (en) 1997-06-05 1998-06-04 Compositions.

Country Status (19)

Country Link
US (1) US20020150616A1 (de)
EP (1) EP0998304B1 (de)
JP (1) JP2002511073A (de)
KR (1) KR20010005852A (de)
CN (1) CN1258220A (de)
AR (1) AR012927A1 (de)
AT (1) ATE247489T1 (de)
AU (1) AU8108198A (de)
CA (1) CA2292506A1 (de)
DE (1) DE69817363T2 (de)
DK (1) DK0998304T3 (de)
ES (1) ES2206949T3 (de)
GB (1) GB9711643D0 (de)
HU (1) HUP0004924A2 (de)
IL (1) IL133293A0 (de)
NO (1) NO995925L (de)
PT (1) PT998304E (de)
WO (1) WO1998055148A1 (de)
ZA (1) ZA984849B (de)

Families Citing this family (396)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330596A (en) * 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US7588793B1 (en) 1998-06-05 2009-09-15 Cadbury Adams Usa, Llc Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same
EE04996B1 (et) 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ES2251985T3 (es) 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6984632B1 (en) * 1999-07-01 2006-01-10 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
WO2001001955A1 (en) * 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
US6835717B2 (en) 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
RS50904B (sr) 2000-05-26 2010-08-31 Pfizer Inc. Derivati tropana i njihova primena
CN1322850C (zh) * 2000-06-02 2007-06-27 沈阳药科大学 盐酸尼卡地平粉针剂及其制备方法
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
RS51166B (sr) 2001-04-10 2010-10-31 Pfizer Inc. Derivati pirazola za tretiranje hiv
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
FR2827516B1 (fr) * 2001-07-19 2003-09-19 Servier Lab Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
KR100698982B1 (ko) 2002-02-11 2007-03-26 화이자 인코포레이티드 Ｐｄｅ4 억제제로서 유용한 니코틴아미드 유도체
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
EP1543841A4 (de) * 2002-08-15 2011-03-16 Yunqing Liu FESTE PHARMAZEUTISCHE NANO-FORMULIERUNG UND HERSTELLUNGSVERFAHREN DAFüR
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
EP1545477A4 (de) * 2002-09-13 2006-11-22 Cydex Inc Kapseln mit wässrigen füllzusammensetzungen, stabilisiert mit derivatisiertem cyclodextrin
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
US7445769B2 (en) 2002-10-31 2008-11-04 Cadbury Adams Usa Llc Compositions for removing stains from dental surfaces and methods of making and using the same
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
DE10260872B4 (de) 2002-12-23 2013-09-26 Beiersdorf Ag Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
DE10260873A1 (de) 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
US7993654B2 (en) * 2002-12-23 2011-08-09 Beiersdorf Ag Self-adhesive polymer matrix containing sea algae extract
US20060177498A1 (en) * 2003-01-22 2006-08-10 Ramaswami Bharatrajan Solid pharmaceutical composition comprising ramipril
JP2006517981A (ja) * 2003-02-17 2006-08-03 サン・ファーマシューティカル・インダストリーズ・リミテッド 低用量コルチコステロイド組成物
EP1460064A1 (de) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide als beta-2 Agonisten
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
ES2409884T3 (es) * 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
US7390518B2 (en) 2003-07-11 2008-06-24 Cadbury Adams Usa, Llc Stain removing chewing gum composition
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
JP5460947B2 (ja) 2003-09-03 2014-04-02 グラクソ グループ リミテッド 新規調製方法、塩、組成物及び使用
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EP1682545B1 (de) 2003-10-03 2007-12-12 Pfizer Limited Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US9271904B2 (en) 2003-11-21 2016-03-01 Intercontinental Great Brands Llc Controlled release oral delivery systems
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8389031B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Coated delivery system for active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1708991B1 (de) 2004-01-22 2007-10-17 Pfizer Limited Sulfonamidderivate zur behandlung von krankheiten
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
PT1708992E (pt) 2004-01-22 2007-11-16 Pfizer Derivados de sulfonamida para o tratamento de doenças
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
EP1735284A1 (de) 2004-03-18 2006-12-27 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamide und deren verwendung als parasitizide
EP1730103B1 (de) 2004-03-23 2010-05-26 Pfizer Limited Als adrenozeptor geeignete formamidderivate
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
KR100479367B1 (ko) * 2004-04-13 2005-03-29 (주) 에프디엘 이트라코나졸을 포함하는 경구투여용 항진균제 조성물
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (de) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US20050282895A1 (en) * 2004-06-21 2005-12-22 Dosch Michael H Antimicrobial compositions and methods of use thereof
US7641892B2 (en) 2004-07-29 2010-01-05 Cadburry Adams USA, LLC Tooth whitening compositions and delivery systems therefor
BRPI0514283A (pt) * 2004-08-11 2008-06-10 Cadbury Adams Usa Llc composições para aquecimento e sistemas de liberação para as mesmas
PL1778686T3 (pl) 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
US7955630B2 (en) 2004-09-30 2011-06-07 Kraft Foods Global Brands Llc Thermally stable, high tensile strength encapsulated actives
US20060068058A1 (en) * 2004-09-30 2006-03-30 Cadbury Adams Usa Llc Thermally stable, high tensile strength encapsulation compositions for actives
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
CN1325054C (zh) * 2004-09-29 2007-07-11 南京师范大学 盐酸哌唑嗪的环糊精包合物及其制备方法
MX2007005290A (es) 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
JP4335120B2 (ja) 2004-11-08 2009-09-30 カゴメ株式会社 混合飲料の製造方法
US9198448B2 (en) * 2005-02-07 2015-12-01 Intercontinental Great Brands Llc Stable tooth whitening gum with reactive ingredients
US8703099B2 (en) 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
JP4521463B2 (ja) 2005-03-17 2010-08-11 ファイザー株式会社 疼痛の治療に有用なｎ−（ｎ−スルホニルアミノメチル）シクロプロパンカルボキサミド誘導体
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP5422203B2 (ja) 2005-04-19 2014-02-19 キングス カレッジ ロンドン 使用
AU2006239941A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
EP1888587A1 (de) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurinderivate als modulatoren des toll-like rezeptors zur behandlung von krebs und virusinfektionen wie hepatitis c
US7851006B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
US7851000B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and edible confectionery and chewing gum products containing same
US7851005B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
DE602006012042D1 (de) 2005-06-15 2010-03-18 Pfizer Ltd Substituierte arylpyrazole zur verwendung gegen parasiten
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070221236A1 (en) * 2005-10-05 2007-09-27 Cadbury Adams Usa Llc. Cooling compositions including menthyl esters
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
EP1973422B1 (de) * 2005-12-23 2014-06-11 Intercontinental Great Brands LLC Zusammensetzungen für die orale oder dermale abgabe, die ein wärmegefühl vermitteln
AU2006330915B2 (en) * 2005-12-23 2011-02-03 Intercontinental Great Brands Llc Compositions providing a sensation substantially similar to that provided by menthol
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
PE20080125A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodo para modular la funcion de la vejiga
CL2007000773A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
KR20080110759A (ko) * 2006-03-24 2008-12-19 와이어쓰 통증 치료
EP1998764A2 (de) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Verfahren zur behandlung kognitiver und anderer störungen
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
JP2010501591A (ja) 2006-08-23 2010-01-21 インテレクト・ニューロサイエンシズ・インコーポレーテッド ３−（３−インドリル）プロピオン酸カルシウム塩およびそれから３−（３−インドリル）プロピオン酸の遊離酸を作る方法
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2380566A3 (de) 2006-09-15 2012-04-11 Stevia APS Verwendung von Steviol oder Isosteviol in der Behandlung von Insulinresistenz oder von mit Insulinresistenz assoziierten Krankheiten
ATE512969T1 (de) 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
EP2076287A2 (de) 2006-10-12 2009-07-08 Wyeth Verfahren und zusammensetzungen mit verringerter opaleszenz
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
EP2222631B1 (de) 2006-10-23 2011-08-17 Pfizer Inc. Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
EP2064315B1 (de) 2006-11-03 2015-05-13 Wyeth LLC Glycolysehemmstoffe in zellkulturen
ES2555066T3 (es) 2006-11-17 2015-12-28 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
AU2007325628A1 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
ES2645719T3 (es) * 2006-12-04 2017-12-07 Supernus Pharmaceuticals, Inc. Formulaciones de topiramato de liberación inmediata mejoradas
US20100093696A1 (en) 2007-02-06 2010-04-15 Pfizer Inc. 2-amino pyrimidine compounds
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2009031011A2 (en) 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20090130251A1 (en) * 2007-11-20 2009-05-21 Cadbury Adams Usa Llc Dual coated confectionery product
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US20090275622A1 (en) * 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2163253B1 (de) 2008-09-15 2013-07-17 ULLRICH, Oliver Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
WO2010058858A1 (ja) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
KR101128450B1 (ko) * 2008-12-11 2012-03-28 (주)바이오제닉스 안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
SI2387580T1 (sl) 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
EP2233502A1 (de) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20100291201A1 (en) * 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
EP2266563A1 (de) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
CA2771609C (en) 2009-08-18 2018-10-02 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
EP2467380B1 (de) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Substituierte benzoazepine als toll-like-rezeptor-modulatoren
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
JP5852966B2 (ja) 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
EP2566858A2 (de) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclische derivate als alk-hemmer
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
EP2593433B1 (de) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
NZ607000A (en) 2010-08-24 2015-02-27 Imp Innovations Ltd Glycodendrimers of polypropyletherimine
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
WO2012066442A1 (en) 2010-11-15 2012-05-24 Pfizer Limited Inhibitors of hiv replication
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
CA2827770A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
ES2581848T3 (es) 2011-04-05 2016-09-07 Pfizer Limited Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
EP2710002B1 (de) 2011-05-18 2017-03-01 RaQualia Pharma Inc Polymorphe form von 4-{[4-({[4-(2,2,2-trifluorethoxy-)1,2-benzisoxazol-3-yl-]oxy-}methyl-)piperidin-1-yl-]methyl-}tetrahydro-2h-pyran-4-carbonsäure
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
CA2840317C (en) 2011-07-13 2016-11-01 Pfizer Limited Enkephalin analogues
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2739274A1 (de) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Behandlung von kognitiver störung
AU2012291744A1 (en) 2011-08-02 2014-02-20 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
ES2748656T3 (es) 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
EA201590199A1 (ru) * 2012-07-12 2015-05-29 Санофи Противоопухолевая композиция, содержащая соединение 1-(6-{[6-(4-фторфенил)[1,2,4]триазоло[4,3-b]пиридазин-3-ил]сульфанил}-1,3-бензотиазол-2-ил)-3-(2-морфолин-4-илэтил)мочевины
CA2879222A1 (en) * 2012-07-17 2014-01-23 Glaxosmithkline Llc Nicotinamide derivate in the treatment of acute coronary syndrome
US9475816B2 (en) 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
EP2897950A1 (de) 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl-)amino-pyrimidin-5-carboxamide als milz-tyrosinkinasehemmer
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
EP2903989A1 (de) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo-[2,3-d-]pyrimidin-tropomyosin-vermittelte kinasehemmer
EP2912036A1 (de) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-d-]pyrimidin-tropomyosin-vermittelte kinasehemmer
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
BR112015010620A2 (pt) 2012-11-08 2017-07-11 Pfizer compostos heteroaromáticos e seus usos como ligantes de dopamina d1
MD20150037A2 (ro) 2012-11-08 2015-11-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
EP2922849B1 (de) 2012-11-21 2017-07-12 RaQualia Pharma Inc. Polymorphe der 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carbonsäure als 5-hydroxytryptamin-4 (5-ht4) rezeptor agonisten zur behandlung von magen-darm-erkrankungen
MX368898B (es) 2012-12-03 2019-10-21 Pfizer Moduladores selectivos del receptor de androgenos novedosos.
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
EP2792360A1 (de) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
SG11201509186TA (en) 2013-06-27 2016-01-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
CA2916033C (en) 2013-07-08 2022-08-23 Abbvie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
EP3021832B9 (de) * 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Konservierte veretherte cyclodextrinderivate mit flüssiger, wässriger pharmazeutischer zusammensetzung
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CA2930033C (en) 2013-12-04 2022-12-13 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
WO2015157509A1 (en) * 2014-04-10 2015-10-15 The Trustees Of The University Of Pennsylvania Compositions and methods for treating opioid receptor associated diseases
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
SG11201608468TA (en) 2014-04-25 2016-11-29 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
EP3134405B1 (de) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
EA201691831A1 (ru) 2014-04-25 2017-02-28 Пфайзер Инк. Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EP3137469B1 (de) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclische verbindungen und deren verwendung als dopamin-d1-liganden
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
AU2015260906B2 (en) 2014-05-15 2017-08-31 Pfizer Inc. Crystalline form of 6-((4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrile
RU2679619C2 (ru) 2014-05-20 2019-02-12 Раквалиа Фарма Инк. Солевое производное бензизоксазола
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
CA2950393A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
EP3154979B1 (de) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazinderivate als modulatoren der gabaa-rezeptoraktivität
EP3157915B1 (de) 2014-06-17 2019-02-27 Pfizer Inc Substituierte dihydroisochinolinonverbindungen
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016044433A2 (en) 2014-09-16 2016-03-24 Biopharma Works Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
US9765000B2 (en) 2015-01-22 2017-09-19 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US20180193335A1 (en) * 2015-10-12 2018-07-12 Vikash J. BHAGWANDIN Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
EP3386983A1 (de) 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazin-derivate der formel (i) als gaba-rezeptormodulatoren zur verwendung bei der behandlung von epilepsie und schmerzen
CN108473467B (zh) 2015-12-24 2021-08-13 武田药品工业株式会社 共结晶、其制造方法及含有共结晶的药物
EP3399968B8 (de) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
EP3402796B1 (de) 2016-01-15 2020-11-18 Pfizer Inc 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepin-dopamin-d3-liganden
CA3012837A1 (en) 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN108884445A (zh) 2016-03-09 2018-11-23 北京智康博药肿瘤医学研究有限公司 肿瘤细胞悬浮培养物和相关方法
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
US20190270778A1 (en) 2016-07-29 2019-09-05 Pfizer Inc. Cyclic Peptides As C5a Receptor Antagonists
EP4233861A3 (de) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Zusammensetzungen zur behandlung von essentiellem tremor
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
CA3047730A1 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Quinazolinones that inhibit the formation of tau oligomers and their method of use
CA3047729A1 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
MX390512B (es) 2017-03-26 2025-03-20 Takeda Pharmaceuticals Co Carboxamidas heteroaromáticas sustituidas con piperidinilo y piperazinilo como moduladores de gpr6.
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
PE20200696A1 (es) 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
WO2019002889A1 (en) * 2017-06-30 2019-01-03 Industrial Technology Research Institute METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
WO2019051469A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
AU2019211188A1 (en) 2018-01-29 2020-07-30 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
US10538542B2 (en) 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
WO2019180072A1 (en) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Parenteral pharmaceutical composition comprising neladenoson bialanate
MD3784664T2 (ro) 2018-04-26 2025-06-30 Pfizer Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
MX2021000549A (es) 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CU20210044A7 (es) 2018-11-29 2022-01-13 Pfizer Pirazoles como moduladores de hemoglobina
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
BR112021013019A2 (pt) 2019-01-23 2021-09-14 Pfizer Inc. Forma polimórfica de um sal de hidrato de monofosfato de um derivado de tetra-hidroisoquinolina conhecido
CN113330000B (zh) 2019-01-31 2024-12-24 辉瑞公司 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物
TW202102498A (zh) 2019-03-22 2021-01-16 日商武田藥品工業股份有限公司 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
AU2020266529B2 (en) 2019-04-29 2026-01-29 Solent Therapeutics, Llc 3-amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
TWI904095B (zh) 2019-07-25 2025-11-11 印度商裘拉德製藥私人有限公司 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
AU2020348675B2 (en) 2019-09-16 2025-11-20 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
JP2022550297A (ja) 2019-09-25 2022-12-01 ファイザー・インク Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター
CN110538094B (zh) * 2019-09-27 2022-01-18 华南理工大学 一种均相亲水和多维稳定的紫檀芪@环糊精包合物及其制备方法
JP7780431B2 (ja) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法
WO2021161230A1 (en) 2020-02-12 2021-08-19 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
NL2025092B1 (en) * 2020-03-10 2021-10-19 Seranovo Holding B V Solid deep eutectic solvent formulation platform
WO2021182951A1 (en) 2020-03-10 2021-09-16 Seranovo Holding B.V. Solid deep eutectic solvent formulation platform
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN115698004A (zh) 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
WO2021222888A1 (en) * 2020-05-01 2021-11-04 University Of Southern California Cyclodextrin based anti-microbial therapy
IL297456A (en) 2020-05-04 2022-12-01 Takeda Pharmaceuticals Co n-(piperidin-4-yl)benzamide derivatives are active in Nahor
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
CN115867533B (zh) 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
WO2022013691A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
CN116710090A (zh) 2020-10-09 2023-09-05 Napa医疗有限公司 Cd38的杂芳基酰胺抑制剂
US20220168272A1 (en) * 2021-02-22 2022-06-02 Gholamhossein Yousefi Preparation of soluble form of carvedilol
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN113081989B (zh) * 2021-03-29 2022-10-21 海南普利制药股份有限公司 别嘌醇缓释片剂
EP4313151A1 (de) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1-inhibitoren und ras-inhibitoren zur verwendung bei der behandlung von schmerzen
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
CN117545751A (zh) 2021-04-07 2024-02-09 生命爱科 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
PE20250118A1 (es) 2021-06-26 2025-01-16 Array Biopharma Inc Inhibidores de mutacion de her2
AU2022325543A1 (en) 2021-08-11 2024-02-15 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
CA3228653A1 (en) 2021-08-11 2023-02-16 Monali BANERJEE Small molecule urea derivatives as sting antagonists
KR20240110971A (ko) 2021-12-01 2024-07-16 푼다시온 델 섹토르 푸블리코 에스타탈 센트로 나시오날 데 인베스티가시오네스 온콜로지카스 카를로스 3 (에프.에스.피 씨엔아이오) 화합물
IL315998A (en) 2022-03-30 2024-11-01 Takeda Pharmaceuticals Co N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
AU2023316863A1 (en) 2022-07-29 2025-02-13 Pfizer Inc. Novel acc inhibitors
AR130151A1 (es) 2022-08-10 2024-11-06 Takeda Pharmaceuticals Co Compuesto heterocíclico
CN115487080A (zh) * 2022-09-23 2022-12-20 山东博科医用材料有限公司 补骨脂酚微胶囊及其制备方法
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
AU2023380028A1 (en) 2022-11-15 2025-05-22 Curadev Pharma Ltd Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
EP4655303A1 (de) 2023-01-26 2025-12-03 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazinderivate zur behandlung neurodegenerativer erkrankungen
EP4694980A1 (de) 2023-04-14 2026-02-18 Takeda Pharmaceutical Company Limited Pyrazolopyrimidinderivate als nlrp3-hemmer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025037213A1 (en) * 2023-08-11 2025-02-20 Mankind Pharma Ltd. Pharmaceutical formulations of gpr119 agonists and uses thereof
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025137437A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Solid forms of a gabaa receptor modulator and methods of its use
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
FR2647015B1 (fr) * 1989-05-17 1994-05-06 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
TW200402B (de) * 1990-08-13 1993-02-21 Senju Pharma Co
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
AU672862B2 (en) * 1992-12-02 1996-10-17 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
EP0689844A1 (de) * 1994-06-23 1996-01-03 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Mit Zyklodextrin gebildete Vinpocetinkomplexe, Zubereitungsverfahren und pharmazeutische Präparate, die sie enthalten
AU7637296A (en) * 1995-11-14 1997-06-05 Farmarc Nederland Bv Complex of naproxen and beta-cyclodextrin

Also Published As

Publication number Publication date
EP0998304B1 (de) 2003-08-20
JP2002511073A (ja) 2002-04-09
PT998304E (pt) 2004-01-30
WO1998055148A1 (en) 1998-12-10
GB9711643D0 (en) 1997-07-30
DE69817363T2 (de) 2004-06-24
CN1258220A (zh) 2000-06-28
ATE247489T1 (de) 2003-09-15
KR20010005852A (ko) 2001-01-15
AU8108198A (en) 1998-12-21
US20020150616A1 (en) 2002-10-17
EP0998304A1 (de) 2000-05-10
HUP0004924A2 (hu) 2001-08-28
IL133293A0 (en) 2001-04-30
DE69817363D1 (de) 2003-09-25
AR012927A1 (es) 2000-11-22
DK0998304T3 (da) 2003-12-01
ES2206949T3 (es) 2004-05-16
CA2292506A1 (en) 1998-12-10
NO995925L (no) 2000-01-11
NO995925D0 (no) 1999-12-03

Similar Documents

Publication Publication Date Title
ZA984849B (en) Compositions.
HUP9903759A3 (en) Abtimicrobial compositions
ZA984567B (en) Detergent compositions.
ZA978178B (en) Composition.
ZA987536B (en) Stanol comprising compositions.
GB9827475D0 (en) Compositions
ZA975261B (en) Composition.
GB9702238D0 (en) Compositions
ZA984218B (en) Detergent compositions.
IL130856A0 (en) Peroxetine compositions
ZA984214B (en) Detergent compositions.
ZA987797B (en) Oral compositions.
ZA9811502B (en) Novel composition.
ZA982343B (en) Detergent compositions.
ZA200006118B (en) Novel composition.
ZA984215B (en) Detergent compositions.
ZA989644B (en) Insoluble insulen compositions.
GB9724838D0 (en) Compositions
GB9705340D0 (en) Compositions
ZA200000192B (en) Novel composition.
ZA981739B (en) Composition.
GB9703109D0 (en) Compositions
ZA99925B (en) Composition.
GB9712981D0 (en) Compositions
GB2336368B (en) Compositions